Discarded Blood Tests May Offer Life-Saving Information
|
By LabMedica International staff writers Posted on 08 Sep 2014 |

Image: Scanning electron micrograph of Staphylococcus epidermidis, the commonest coagulase-negative staphylococci found on the skin (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Blood culture isolates are the cornerstone of adequate antibiotic treatment, but many blood cultures are contaminated with bacteria residing on the skin, and the most common contaminants are coagulase-negative staphylococci (CoNS).
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Such contaminated cultures are mostly disregarded and discarded but in fact these contaminated cultures contain diagnostic information such as the antibiotic resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated subsequently from the same patient.
Clinical scientists at the Sackler Faculty of Medicine (Tel Aviv, Israel) conducted a retrospective study on patients with positive blood cultures from 2009 to 2012. Data included patient demographics, hospitalization records, comorbidities, blood culture results and date of death. The cohort consisted of 2,518 patients with 5,290 blood cultures, where 1,124 patients had 1,664 blood cultures with CoNS contaminants.
High overall CoNS resistance predicted high overall resistance of the subsequent bacterial isolates for Gram-positive and Gram-negative bacteria. The resistance of CoNS contaminants to a specific antibiotic predicted the resistance of the subsequent bacterial isolates to that antibiotic and highly resistant CoNS isolates were associated with higher short-term mortality.
The team noted that most hospital patients are treated at the outset with broad spectrum antibiotics. Days later, after initial test results are known, clinicians replace broad spectrum antibiotics with more precise narrow-spectrum antibiotics, which treat the specific bacteria identified by the blood sample. Narrow spectrum antibiotics are better for the body because they target specific bacteria as opposed to an entire microenvironment. Moreover, broad spectrum antibiotics might result in altered bacterial environments of the skin and gastro-intestinal tract, promoting inflammation and the emergence of resistant pathogens.
Gideon Y Stein, MD, PhD, a lead author of the study said, “Because we have found a direct correlation between resistance profiles of CoNS contaminants and those of the actual infecting bacteria isolated from the same patient, the results of these “junk” samples can be used to predict patient mortality and correct empirical antibiotic therapy. This should serve as an additional, noninvasive, diagnostic tool.” The study was published in the September issue of the Journal of Antimicrobial Chemotherapy.
Related Links:
Tel Aviv University Sackler Faculty of Medicine
Latest Microbiology News
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Channels
Clinical Chemistry
view channelMultiprotein Plasma Panel Identifies Remission in Vasculitis
Vasculitis causes immune-mediated inflammation of blood vessel walls and can lead to kidney and lung damage. Clinicians rely on immunosuppressive drugs, but treatment carries significant side effects and... Read more
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read moreMolecular Diagnostics
view channel
Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency
Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more
New Automation Platform Standardizes DNA and RNA Extraction Across Clinical Workflows
QIAGEN has introduced QIAsymphony Connect, an in vitro diagnostic (IVD)-compliant platform for automated clinical nucleic acid extraction. The system builds on more than 3,300 cumulative placements of... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Gut “Memory” May Explain Why IBD Flares Return
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict.... Read more
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read morePathology
view channel
AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channelTumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more







